Category Archives: FDA Policy

Thumbs Up, Thumbs Down – Minimizing Votes in AdComms

The FDA Commissioner has said he would like to limit votes in AdComms – is that really a good idea? Continue reading

Posted in Advisory Committee Prepapartion, FDA Policy | Tagged , , | Comments Off on Thumbs Up, Thumbs Down – Minimizing Votes in AdComms

Emerging from Emergency – Two COVID-Related Developments This Week

Two announcements occurred this week, both of note and connected only by the fact that they are emblematic of the slow metamorphosis from a COVID emergency world to a post-COVID emergency one. Emergency Ends – First, the Biden Administration announced … Continue reading

Posted in FDA Image, FDA Policy | Tagged , , , , | Comments Off on Emerging from Emergency – Two COVID-Related Developments This Week

Tick Tock re Tik Tok and FDA’s OPDP

Tik Tok was first released in 2016. While slow out of the starting gate with emergent media opportunities, in 2022, pharma is embracing the platform in both unbranded and branded efforts. While historically, a lot of Tik Tok use has … Continue reading

Posted in DTC Advertising, FDA Policy, Regulatory Communications | Comments Off on Tick Tock re Tik Tok and FDA’s OPDP

OPDP Outlines New Research

FDA published notice recently that the Office of Prescription Drug Promotion (OPDP) was proposing some new research related to the promotion of medicines by pharmaceutical companies. The research was new (kind of) but the direction was more of the same … Continue reading

Posted in FDA Policy, Research | Tagged , , | Comments Off on OPDP Outlines New Research

What They Said – Looking Back the First 6-Months of FDA Communications

Periodically I write a posting to look back at what FDA is talking about to get some perspective. Each individual press release tells us something, but looking back at the aggregate can also provide insights. Not long ago, a retrospective … Continue reading

Posted in FDA Image, FDA Policy | Comments Off on What They Said – Looking Back the First 6-Months of FDA Communications